Figure 3: Association between MBL2 and NOD2 polymorphisms, mannose-binding lectin concentration, functional activity of the MBL-MASP complex and anti-S. cerevisiae antibody levels in Crohn’s disease patients (A–C). | Scientific Reports

Figure 3: Association between MBL2 and NOD2 polymorphisms, mannose-binding lectin concentration, functional activity of the MBL-MASP complex and anti-S. cerevisiae antibody levels in Crohn’s disease patients (A–C).

From: Polymorphisms in the Mannose-Binding Lectin Gene are Associated with Defective Mannose-Binding Lectin Functional Activity in Crohn’s Disease Patients

Figure 3

Mannose-binding lectin concentration was significantly associated with rs930508 (wild-type C/C heterozygous C/G or homozygous G/G; P < 0.01), rs1800450 (wild-type C/C, heterozygote C/T; P < 0.001) and rs5030737 (wild-type G/G, heterozygote G/A; P < 0.0001) of MBL2 polymorphisms in Crohn’s disease patients. (D) Functional activity of the MBL-MASP complex was significantly associated with the rs5030737 MBL2 polymorphism in Crohn’s disease patients (wild-type G/G, heterozygote G/A; P < 0.05). (E) Relationship between the rs5030737 MBL2 polymorphism and anti-S. cerevisiae antibody levels in Crohn’s disease patients. Anti-S. cerevisiae antibody level was significantly higher in heterozygous Crohn’s disease patients (G/A; n = 9) than in wild-type patients (G/G; n = 60) for the rs5030737 MBL2 variant (P < 0.01). (F) Association between functional activity of the MBL-MASP complex and the NOD2 polymorphism in Crohn’s disease patients. Functional activity of the MBL-MASP1 complex was significantly higher in heterozygous Crohn’s disease patients (C/T; n = 20) when compared to wild-type patients (C/C; n = 50) for the rs2066844 NOD2 variant (P < 0.05).

Back to article page